revenu million
valu usd unless otherwis note
three compani best-cas data
view best-cas data two next-gen corrector show activ even
better game-chang result first two set stage pivot
start andon top strong quarter highlight continu opportun
cf marketlt cf growth leadership rais pt
increas po cf revenu opportun would buy
addit detail call support strong clinic rational
progress look highli efficaci safe
beyond initi pr take detail compani
reassur strength profil includ
limit efficaci variabl pt two rash case
bilirbuin elev resolv quickli follow d/
 pt abl restart mild-moder preclin
teratogen either two next-gen corrector
eas pivot studi conduct observ mix across
dose without pattern make drug relationship less like
chest tight effect seen orkambi absent studi
rel short unexpect off-target tox could still emerg
pivot strong total data consist mostli dose-
depend benefit across tripl two shot goal multipl
viabl backup increas likelihood
combo make line captur het/min opportun increas
po expand homozyg valu proposit
pivot start regulatori discuss exact designs/
requir still on-going move ph iii het/min
homozyg pt follow feedback
requir still pend continu believ faster path
may possibl het/min given unmet need though sens
manag downplay potenti substanti shorten
durationnot ph iii would like need
chronic lifelong regimen dose yet final note
tez dose arm look best though seem qd regimen
ultim achiev deutiva tripl
solid commerci execut augment on-going
margin expans even modest carryov
inventori build roughli divid equal kalydeco/orkambi
strong execut driven kalydeco residu fx wareh
better expect eu orkambi perform drove upsid
await tez/iva approv full-year sale guidanc opex guidanc
slightli increas y-o-i due addit pipelin
line expect coupl continu growth among
kalydeco residu fx orkambi pt tez/iva launch
expand orkambi eu reimburs enabl strong revenu
growth oper margin expans
price prior trade day market close estimate unless otherwis note
bullish prospect cf tripl combo
come recent data particularli concern
long-term threat franchis given high bar
limit potenti competitor believ high
growth prospect estim ep compound-annual-growth-rate
share bake optim appreci
past month outstand initi data
tripl combo set high bar may difficult surpass
believ given compani strong fundament
addit appreci beyond broader biotech tape
posit leader high-growth high-margin cf
space led kalydeco orkambi like soon tez/iva
high bar potenti futur competitor
risk price pressur competit entrant could
outsiz neg impact out-year revenu next
gen corrector set initi ph iii trial though still
complet derisk safeti difficult improv
upon initi data addit tripl combo result
potenti catalyst potenti tez/iva approv
ph iii trial fda regulatori feedback initi
triple-combo ph iii trial data ph ii
bunionectomi studi initi ph i/ii studi
beta-thalassemia sickl cell diseas
bloomberg capit market estim upside/downside/target
base case assum probabl success
expans het/min improv persistence/compli
tez/iva introduct tez/iva price blend current
kalydeco orkambi price assum scenario
 could reduc sg
mainten cf leadership price target deriv
dcf analysi base busi discount
rate termin growth rate
success tripl combo enabl expans het/min cf
patient better expect tez/iva and/or ex-u price
power higher complianc improv would lead
upsid estim upsid scenario potenti
dcf-base valuat would
failur tripl combo emerg competit reduc
long-term market share erod price power would lead
downsid estim downsid scenario
potenti dcf-base valuat would
exhibit potenti mileston pipelin
producteventtimelinekalydecosubmit nda/ regulatori applic use infant year franc netherland nda children symdeco potenti approv pdufa date potenti approv expand ph ii tripl combo ph iii trial fda regulatori triple-combo ph iii addit next-gen ph ii bunionectomi poc ph ii neuropath ph ii neuropath pain deuter ivacaftor pivot trial part least one tripl ind sickl cell ph i/ii studi beta-thalassemia sickl cell fibrosi gate residu function mutationsmarketedorkambicyst fibrosi homozygousmarketedtez/iva symkevi cystic fibrosi ciliari dyskenesiaphas corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase spinal cord injuryphas deuter ivacaftor concert pharma cystic fibrosi gate residu function mutationsphas crispr beta-thalassmia sickl cell diseasepreclinicalmilestonesdrug/target thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand biotechnolog
price target deriv dcf analysi base busi discount
rate termin growth rate price target support outperform rate
risk rate price target
risk includ lower expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
global biotechnolog compani focus develop
small molecul drug seriou unmet diseas compani previous develop
drug fda approv hiv hep multipl approv drug
includ kalydeco orkambi treatment variou mutat cystic fibrosi
develop pipelin addit cf drug popul current
drug address addit vertex work build pipelin beyond cf
next year vertex aspir becom fulli integr biopharmaceut
compani discoveri commerci global sale market
